Armed with li­brary of mol­e­c­u­lar glues, De­gron launch­es out of a Shang­hai lab

A transpa­cif­ic biotech fo­cused on mol­e­c­u­lar glues now has more funds to play with as it works to vie for Big Phar­ma’s at­ten­tion.

De­gron Ther­a­peu­tics an­nounced a Se­ries A worth $22 mil­lion Thurs­day, with Chi­nese VC Med-Fine Cap­i­tal as lead in­vestor and oth­er in­vestors such as Dy­ee Cap­i­tal and Baidu Ven­ture tag­ging along. Seed in­vestors CO-WIN Ven­tures and Yuan­bio Ven­ture Cap­i­tal al­so par­tic­i­pat­ed, De­gron said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER